AgomAb Therapeutics

AgomAb Therapeutics

AgomAb Therapeutics

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Raised
$23.6M
Follow us
Latest funding
€21,000,000
Venture capital (Series A) - 2019
V-Bio Ventures Advent France Biotechnology
Team Size
1–10
Employees
Location
Headquarters

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when AgomAb Therapeutics makes some noise.